Core Laboratories Inc. /DE/ 8-K/A

What Happened
Core Laboratories Inc. (CLB) filed an 8-K (Item 2.02) disclosing that, during preparation of its audited 2025 financial statements, it discovered an understatement of estimated income tax expense of $4.2 million for the quarter and year ended December 31, 2025. The company is revising the previously issued earnings release for the quarter and year and expects to file its Form 10‑K for the year ended December 31, 2025 on or around March 17, 2026. The 8‑K was signed by CFO Christopher S. Hill on March 16, 2026.

Key Details

• Income tax expense for Q4 and year 2025 increased by $4.2 million, reducing net income by $4.2 million and lowering diluted EPS by $0.09 for both the quarter and year.
• The tax adjustment stems from reconciliations of tax accounts, deferred tax assets analysis, and final 2024 foreign tax returns — notably a timing difference related to insurance proceeds from fire damage at the Aberdeen, U.K. facility.
• Balance sheet impacts as of Dec 31, 2025: income taxes receivable decreased $8.2M, deferred tax assets decreased $5.2M, income taxes payable decreased $1.2M, and deferred tax liabilities decreased $2.6M.
• Prior-period corrections: a $4.7M misclassification between income taxes receivable and deferred tax liabilities, and a $5.6M write-off of unrecoverable pre-2021 income taxes receivable (recorded as a $5.6M reduction to beginning retained earnings).

Why It Matters
For investors, the revision reduces 2025 net income and EPS modestly ($0.09 per share) but does not change reported revenue, operating income, income before tax, or cash from operations in the previously issued earnings release. The tax adjustments are primarily non-cash and reflect reconciliations and prior‑period corrections to tax accounts; they affect the balance sheet presentation and opening retained earnings. The company’s disclosure and forthcoming Form 10‑K provide the updated, audited figures investors should use when evaluating CLB’s 2025 financial results.